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Hepatocyte transduction following intravenous administration of adenovirus 5 (Ad5) is mediated by inter-
action between coagulation factor X (FX) and the hexon. The FX serine protease (SP) domain tethers the
Ad5/FX complex to hepatocytes through binding heparan sulfate proteoglycans (HSPGs). Here, we identify the
critical HSPG-interacting residues of FX. We generated an FX mutant by modifying seven residues in the SP
domain. Surface plasmon resonance demonstrated that mutations did not affect binding to Ad5. FX-mediated,
HSPG-associated cell binding and transduction were abolished. A cluster of basic amino acids in the SP
domain therefore mediates surface interaction of the Ad/FX complex.
Adenoviruses are nonenveloped, double-stranded DNA vi-
ruses belonging to the Adenoviridae family, of which there are
54 different serotypes divided into species based on their phy-
logenic origin and hemagglutination properties. Adenoviruses
can infect a wide variety of cell types and are extensively used
as vectors for gene transfer applications, from use in vitro or in
vivo in the laboratory setting to gene therapy clinical protocols.
Species C adenovirus serotype 5 (Ad5) is the most commonly
used vector for clinical gene therapy and vaccination applica-
tions. However, liver sequestration after intravenous adminis-
tration of Ad5 results in high-level gene transfer in hepato-
cytes, which can greatly reduce the efficacy of the vector for the
target organ or disease site. Recent studies have shown that
hepatocyte transduction by Ad5 is mediated by a high-affinity
interaction between coagulation factor X (FX) and the Ad5
trimeric hexon protein (4, 11, 13–15), which is the most abun-
dant protein in the adenovirus capsid. FX is a zymogen of a
vitamin K-dependent serine protease that is primarily synthe-
sized in the liver and circulates in the bloodstream at 8 g/ml.
It is composed of a light chain consisting of a -carboxylated
glutamic acid (Gla) and two epidermal growth factor (EGF)-
like domains that are disulfide linked to the serine protease
(SP) heavy chain. While the FX Gla domain has been shown to
bind hexon proteins in the Ad5 capsid, the FX SP domain
bridges the Ad5/FX complex to the hepatocyte surface (2, 11,
15). Previous studies have shown soluble heparin or heparan
sulfate can completely ablate FX-mediated Ad5 uptake in vitro
and in vivo, indicating the critical role of heparan sulfate pro-
teogylcans (HSPGs) for Ad5 cellular binding (2). FX has been
shown to bind to at least 14 other Ad serotypes, indicating that
this interaction is conserved (15). These findings have high-
lighted the importance of understanding the precise mech-
anisms governing cellular infectivity and tropism in order
for adenoviruses to be successfully used as therapeutic gene
delivery vectors.
Our previous studies demonstrated that the anticoagulants
nematode anticoagulant peptide 2 (NAPc2) and Ixolaris can
block FX-mediated Ad5 transduction in vitro (7, 8, 15). Ixolaris
has been shown to bind residues within the heparin binding
exosite of FXa, previously defined as R93, K96, R125, R165,
K169, K236, and R240 (12). The crystal structure of NAPc2
with FXa indicates it also binds to this exosite and residues
R93, R125, K236, and R240 (8). Moreover, preincubation of
FX with each anticoagulant prior to injection into coagulation
factor-depleted mice resulted in a significant decrease in
Ad5 hepatic gene transfer (15). Although this study impli-
cated a role for the FX SP domain in Ad5 transduction, the
precise mechanism and amino acid residues responsible for
FX-mediated Ad5 attachment to HSPGs have not been re-
ported. Here, we demonstrate that seven basic amino acid
residues in the FX heparin binding proexosite (HBPE) are
responsible for this fundamentally important, tropism-de-
termining interaction.
To assess the importance of the HBPE on Ad5/FX complex
binding to HSPGs, we generated an FX construct in which the
seven basic residues previously shown to bind heparin (12)
were mutated (SP mutant rFX). Charge to alanine site-di-
rected PCR mutagenesis was performed at the seven codons
encoding basic residues R93, K96, R125, R165, K169, K236,
and R240 (amino acids are numbered from the amino-terminal
residue of the mature FX) in the FX construct (Fig. 1A).
Mutagenesis and the entire FX coding sequence were verified
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by DNA sequence analysis. The wild-type (WT) and SP mutant
FX-encoding cDNAs were cloned into a mammalian expres-
sion vector (human prothrombin signal sequence and propep-
tide followed by the sequence for the factor X derivative
pCMV4-ss-pro-II-FX) (3). Constructs were transfected into
293T cells, and stable cell lines were generated based on zeocin
resistance (200 g/ml). Conditioned medium from cells cul-
tured in serum-free media supplemented with 5 g/ml vitamin
K was affinity purified using the 4G3 mouse monoclonal anti-
body coupled to Sepharose as previously described (5). The
recombinant protein was analyzed by paired antibody kit en-
zyme-linked immunosorbent assay (ELISA) (Affinity Biologi-
cals, Canada) for human FX, SDS-PAGE, activation assay,
and surface plasmon resonance (SPR). Each recombinant FX
protein migrated as a single band on nonreduced SDS-PAGE
with an apparent molecular mass of 59 kDa, similar to purified
plasma-derived FX (pd FX) (Hematologic Technologies), as
assessed by Western blot analysis (Fig. 1B). The amidolytic
activity of FXa was measured using 1 mM chromogenic sub-
strate S-2765 (Quadratech, United Kingdom) in the absence
and presence of 100 nM tissue factor, 100 nM factor VIIa, and
6 mM CaCl2. All measurements were determined kinetically by
measuring absorbance at 405 nm (9). Recombinant FX (rFX)
proteins were converted to active forms (FXa) in the presence
of tissue factor and FVIIa, confirming their biological activity
(Fig. 1C). SPR was performed using a Biacore T100 (GE
Healthcare). Ad5 hexon was covalently immobilized (1036RU)
onto the flow cell of a CM5 biosensor chip by amine coupling
according to the manufacturer’s instructions and as described
previously (15). Injections of purified human plasma-derived
FX (pd FX), WT, or SP mutant rFX conditioned media were
immediately followed by the monoclonal anti-FX antibodies
HX-1 and 4G3 prior to regeneration of the sensor chip surface.
SPR analysis indicated that the conditioned media of cells
FIG. 1. Validation of rFX protein. (A) Ribbon diagram of the FX serine protease-epidermal growth factor 2 (EGF2) domains (1HCG; Accelrys
ViewerLite software) (10). SP is in blue, and EGF2 is in red. The diagram highlights amino acid residues (green) targeted for mutagenesis studies.
(B) Western blot analysis of rFX was performed under nonreducing conditions (10% Bis-Tris mini gels; Novex), and rFX was probed with a
primary monoclonal human anti-FX clone HX1 antibody (1:1,000 dilution) and a goat anti-mouse infrared (IR) dye (800CW)-labeled secondary
antibody (LI-COR). The blot was visualized using an Odyssey infrared imaging system (LI-COR). (i) Lanes 1 to 3, SP mutant rFX purified by 4G3
column; lane 4, pd FX control. (ii) Lanes 1 to 3, WT rFX purified by 4G3 column; lane 4; pd FX control. (C) Activation of WT rFX and SP mutant
rFX (SP mut rFX). The amidolytic activity of FXa was measured using 1 mM chromogenic substrate S-2765 (Quadratech, Surrey, United
Kingdom) in the absence and presence of 100 nM tissue factor (TF), 100 nM factor VIIa (FV119), and 6 mM CaCl2. All measurements were
determined kinetically at 405 nm. Error bars represent standard errors of the means (n  3).
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transfected with either WT or SP mutant FX bound to hexon
in a calcium-dependent manner, and this was confirmed to be
FX by subsequent injection of two monoclonal antibodies
against human FX (HX-1 and 4G3) (Fig. 2A to C).
To assess the effects of the SP proexosite mutations on
Ad5/FX-mediated cell binding and gene transfer, we used
SKOV3 ovarian carcinoma and human HepG2 hepatoma cells
since they can be readily transduced via the FX pathway (2).
For experiments involving SKOV3 cells, which have low levels
of coxsackievirus and adenovirus receptor (CAR) expression
(6), we utilized a -galactosidase-expressing Ad5, and for ex-
periments involving HepG2 cells, which have higher CAR ex-
pression, we utilized Ad5KO1 (a CAR binding mutated Ad5).
First, since cell surface binding of Ad5/FX complexes is medi-
ated by HSPGs (2, 11), we evaluated the interaction of fluo-
rescently labeled Ad5 with HSPGs when complexed with WT
or the SP mutant rFX. Ad5 was fluorescently labeled using
an Alexa Fluor-488 protein labeling kit according to the
manufacturer’s instructions (Invitrogen). Cells were incu-
bated with 1 104 virus particles (vp)/cell of Alexa 488-labeled
Ad5 in serum-free Dulbecco’s modified Eagle’s medium (SFD-
MEM) (Invitrogen) for 1 h on ice in the absence of FX or in
the presence of WT or SP mutant rFX prior to fixation. Lo-
calization of Ad5 at the cell surface was characterized by stain-
FIG. 3. Critical role of the heparin binding proexosite in the FX SP domain in Ad5 cell binding and gene transfer in vitro. (A) Alexa 488-labeled
Ad5 (green) at 10,000 vp/cell was allowed to bind SKOV3 cells for 1 h at 4°C in the absence of FX or the presence of WT rFX or SP mutant rFX.
Cells were then stained with a pan-heparan sulfate antibody (clone 10E4) (red). Nuclei were counterstained using DAPI. Images were captured
on a confocal microscope at 63 objective. (B) Binding of Ad5 at 1,000 vp/cell to SKOV3 cells or Ad5KO1 at 1,000 vp/cell to HepG2 cells for
1 h at 4°C in the presence or absence of pd FX (positive control FX), WT rFX, or SP mutant rFX was quantified. Vector genomes were detected
by quantitative SYBR green PCR. (C) Alexa 488-labeled Ad5 (green) at 10,000 vp/cell was allowed to bind SKOV3 cells for 1 h at 4°C in the
absence or presence of pd FX, WT rFX, or SP mutant rFX. Cells were then incubated at 37°C for 0 or 60 min prior to fixation and staining for
the MTOC marker pericentrin (red). Nuclei were counterstained using DAPI. Images were captured on a confocal microscope at 63 objective.
(D) The percentage of cells with colocalization of fluorescently labeled Ad5 with the MTOC marker pericentrin was calculated by analyzing at least
five separate 40microscope fields per experimental condition. (E) SKOV3 and HepG2 cell transduction at 48 h postinfection after a 3-h exposure
to Ad5 or Ad5KO1 in the presence or absence of pd FX, WT rFX, or SP mutant rFX conditions. RLU, relative light units. Error bars represent
standard errors of the means.
FIG. 2. Proexosite mutations have no effect on rFX binding to Ad5 hexon by SPR. (A) Representative subtracted sensorgrams of pd FX,
wild-type rFX and SP mutant rFX binding hexon, injected at time zero for 60 s at a flow rate of 30 l/min. RU, response units. (B) Quantification
of relative binding to hexon at the end of the injection, as indicated by the arrow. (C) Representative subtracted sensorgrams showing binding of
anti-FX antibodies 4G3 or HX-1 to the chip following prior injection of running buffer, pd FX, and WT or mutant SP rFX, injected at a flow rate
of 30 l/min. *, P  0.05. Error bars represent standard errors of the mean (n  5).
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ing with the mouse monoclonal pan-heparan sulfate antibody
(clone 10E4) (AMS Biotechnology, Oxford, United Kingdom).
Cell nuclei were counterstained using DAPI (4,6-diamidino-
2-phenylindole). Images were taken using the Zeiss confocal
imaging system (LSM500). Following pretreatment with WT
rFX, Ad5 complexes were clearly visible on the cell surface and
colocalized with HSPGs (Fig. 3A). In contrast, no colocaliza-
tion with HSPGs was observed when Ad5 was pretreated with
SP mutant rFX. For binding and transduction assays, cells were
incubated with 1,000 vp/cell of Ad5 in SFDMEM in the ab-
sence or presence of 1 g/ml pd FX or WT or SP mutant rFX.
Quantification of Ad5 cell surface binding by qPCR (1) re-
vealed that WT rFX caused a significant 14-fold increase
compared to cells not treated with WT rFX or pd human FX
(positive control FX) (Fig. 3B), whereas no significant increase
was observed when SP mutant rFX was used at an equivalent
concentration to WT rFX (Fig. 3B). To analyze the effects of
FX mutagenesis on Ad5 cell binding, internalization, and cy-
tosolic transport, trafficking assays using fluorescently labeled
Ad5 were performed in SKOV3 cells. In the presence of WT
rFX or pd human FX, Ad5 bound the cell surface and after 1 h
of incubation at 37°C efficiently trafficked to the nucleus, where
it colocalized with the microtubule organizing center (MTOC),
which was characterized by staining with a polyclonal rabbit
pericentrin antibody (Abcam, United Kingdom) (Fig. 3C).
However, when performed using the SP mutant FX, no cell
surface binding or trafficking was observed (Fig. 3C and D).
Ad5-MTOC colocalization was quantified as previously de-
scribed (2). These data were confirmed by analyzing expression
of the -galactosidase transgene: both WT rFX and pd FX
mediated a significant increase in gene expression, whereas the
SP mutant rFX resulted in no significant change in SKOV3 or
HepG2 cells (Fig. 3E).
To confirm the importance of the SP proexosite, we charac-
terized the effect of the SP mutations ex vivo by examining
fluorescently labeled Ad5 binding to mouse liver sections (Fig.
4). Frozen liver sections from MF-1 mice were incubated with
2  109 vp of Alexa 488-labeled Ad5 in SFDMEM in the
absence or presence of WT or SP mutant rFX for 1 h on ice
followed by 1 h at 37°C. Sections were counterstained using
DAPI and imaged using an Olympus Cell M imaging system.
To quantify adherent Ad5, 40 microscope fields were pro-
cessed using Image J counting software. Under SP mutant rFX
conditions, there was 5-fold less adherent Ad5 particles com-
pared to under WT rFX conditions.
This study investigates the precise mechanism by which the
Ad/FX complex interacts with HSPGs by demonstrating the
critical importance of the amino acid residues of the HBPE of
FX. Here we mutated the seven proexosite residues. Of inter-
est, the four residues Arg165, Lys169, Lys236, and Arg240 are
conserved in mouse and human FX. The remaining three res-
idues are charge conserved (i.e., Arg-Lys or Lys-Arg), thus
maintaining a positive charge. Future studies could aim to
further dissect the individual residues critical to Ad5 binding
with HSPGs. Using surface plasmon resonance of recombinant
protein, we demonstrated that the SP mutations had no effect
on FX-specific binding to the Ad5 hexon; however, FX-medi-
ated binding and transduction were ablated. Taken together,
this study uncovers the basic residues (R93, K96, R125, R165,
K169, K236, and R240) in the SP domain of FX that have a
FIG. 4. Critical role of the heparin binding proexosite in the FX SP domain in Ad5 cell binding ex vivo. (A) Liver slices from MF1 mice were
incubated with 2  109 vp of Alexa 488-labeled Ad5 in the presence of WT or SP mutant rFX. (B) Attachment of Ad5 particles to liver slices was
quantified using ImageJ counting software. Data represent the average number of particles by analyzing at least 6 separate 40 microscope fields
per experimental condition. *, P  0.05. Error bars represent standard errors of the mean.
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fundamental role in FX-mediated Ad5 complex engagement
with HSPGs at the surface of target cells.
This work was funded by the Scottish Universities Life Sciences
Alliance, the British Heart Foundation, and the Biotechnology and
Biological Sciences Research Council.
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